Compare Endeavour Silver Corp (EXK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Endeavour Silver Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Endeavour Silver Corp trades at $10.67 (market cap $3.03B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 27.5× Endeavour Silver Corp's market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Endeavour Silver Corp pays none. Which is the better fit depends on your goals.
| EXK | REGN | |
|---|---|---|
Market Cap | $3.03B | $83.19B |
Sector | Basic Materials | Health |
52-Week High | $14.12 | $812.27 |
52-Week Low | $5.31 | $555.51 |
Enterprise Value | $3.04B | $77.90B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EXK is trading at $9.54, up 8.04% today, with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with Q2 2026 earnings matching estimates and revenue growth from $468M in 2025 to $737M projected for 2026. Recent news highlights a $25M credit facility and operational expansion at Terronera mine.
Outlook remains positive with analyst consensus price target of $15.50 (62% upside), though risks include volatile earnings history and elevated P/E ratio of 51.2. The stock offers growth potential through silver production expansion but faces commodity price sensitivity and execution risks in mine development.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
